Inhibition of NF-κB activity in the hypothalamic paraventricular nucleus attenuates hypertension and cardiac hypertrophy by modulating cytokines and attenuating oxidative stress

Toxicol Appl Pharmacol. 2015 May 1;284(3):315-22. doi: 10.1016/j.taap.2015.02.023. Epub 2015 Mar 7.

Abstract

We hypothesized that chronic inhibition of NF-κB activity in the hypothalamic paraventricular nucleus (PVN) delays the progression of hypertension and attenuates cardiac hypertrophy by up-regulating anti-inflammatory cytokines, reducing pro-inflammatory cytokines (PICs), attenuating nuclear factor-κB (NF-κB) p65 and NAD(P)H oxidase in the PVN of young spontaneously hypertensive rats (SHR). Young normotensive Wistar-Kyoto (WKY) and SHR rats received bilateral PVN infusions with NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC) or vehicle for 4 weeks. SHR rats had higher mean arterial pressure and cardiac hypertrophy as indicated by increased whole heart weight/body weight ratio, whole heart weight/tibia length ratio, left ventricular weight/tibia length ratio, cardiomyocyte diameters of the left cardiac ventricle, and mRNA expressions of cardiac atrial natriuretic peptide (ANP) and beta-myosin heavy chain (β-MHC). These SHR rats had higher PVN levels of proinflammatory cytokines (PICs), reactive oxygen species (ROS), the chemokine monocyte chemoattractant protein-1 (MCP-1), NAD(P)H oxidase activity, mRNA expression of NOX-2 and NOX-4, and lower PVN IL-10, and higher plasma levels of PICs and NE, and lower plasma IL-10. PVN infusion of NF-κB inhibitor PDTC attenuated all these changes. These findings suggest that NF-κB activation in the PVN increases sympathoexcitation and hypertensive response, which are associated with the increases of PICs and oxidative stress in the PVN; PVN inhibition of NF-κB activity attenuates PICs and oxidative stress in the PVN, thereby attenuates hypertension and cardiac hypertrophy.

Keywords: Cardiac hypertrophy; Hypertension; Hypothalamic paraventricular nucleus; NF-κB; Neurohormonal excitation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arterial Pressure / drug effects
  • Biomarkers / metabolism
  • Cardiomegaly / etiology
  • Cardiomegaly / immunology
  • Cardiomegaly / metabolism
  • Cardiomegaly / physiopathology
  • Cardiomegaly / prevention & control*
  • Cytokines / metabolism*
  • Disease Models, Animal
  • Hypertension / complications
  • Hypertension / drug therapy*
  • Hypertension / immunology
  • Hypertension / metabolism
  • Hypertension / physiopathology
  • Inflammation Mediators / metabolism*
  • Oxidative Stress / drug effects*
  • Paraventricular Hypothalamic Nucleus / drug effects*
  • Paraventricular Hypothalamic Nucleus / immunology
  • Paraventricular Hypothalamic Nucleus / metabolism
  • Pyrrolidines / pharmacology*
  • Rats, Inbred SHR
  • Rats, Inbred WKY
  • Signal Transduction / drug effects
  • Sympathetic Nervous System / drug effects
  • Sympathetic Nervous System / metabolism
  • Sympathetic Nervous System / physiopathology
  • Thiocarbamates / pharmacology*
  • Time Factors
  • Transcription Factor RelA / antagonists & inhibitors*
  • Transcription Factor RelA / metabolism

Substances

  • Biomarkers
  • Cytokines
  • Inflammation Mediators
  • Pyrrolidines
  • Rela protein, rat
  • Thiocarbamates
  • Transcription Factor RelA
  • pyrrolidine dithiocarbamic acid